Premium
Dihydromyricetin enhances the osteogenic differentiation of human bone marrow mesenchymal stem cells in vitro partially via the activation of Wnt/β‐catenin signaling pathway
Author(s) -
Zhang Wei,
Wang Shengdong,
Yin Houfa,
Chen Erman,
Xue Deting,
Zheng Qiang,
Gao Xiang,
Pan Zhijun
Publication year - 2016
Publication title -
fundamental and clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.655
H-Index - 73
eISSN - 1472-8206
pISSN - 0767-3981
DOI - 10.1111/fcp.12225
Subject(s) - mesenchymal stem cell , wnt signaling pathway , microbiology and biotechnology , in vitro , catenin , chemistry , bone marrow , signal transduction , stem cell , biology , immunology , biochemistry
Substantial evidence has demonstrated that the decreased osteogenic differentiation of bone mesenchymal stem cells ( BMSC s) is closely related to bone metabolic diseases. Thus, it is very important to develop several potentially useful therapeutic agents to enhance BMSC osteogenesis. Flavonoids show promise in enhancing bone mass. Dihydromyricetin ( DMY ), a type of flavonoid, has not yet been investigated regarding its effects on BMSC osteogenesis. To investigate the effects of DMY on osteogenesis, human BMSC s were induced with or without DMY . We found that DMY (0.1–50 μ m ) exhibited no cytotoxic effect on proliferation, but increased alkaline phosphatase activity, osteoblast‐specific gene expression, and mineral deposition. It also enhanced active β‐catenin expression and reduced dickkopf‐1(DKK1) and sclerostin expression. The Wnt/β‐catenin signaling pathway inhibitor (DKK1 and β‐catenin‐specific si RNA ) decreased the enhanced bone mineral formation caused by DMY . Taken together, these findings reveal that DMY enhances osteogenic differentiation of human BMSC s partly through Wnt/β‐catenin in vitro.